Virtual Library
Start Your Search
I. Kapfhammer
Author of
-
+
P3.03 - Chemotherapy/Targeted Therapy (ID 719)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.03-024 - Real-Life Experience and Clinical Characterization of BRAF V600E Mutation in Austrian NSCLC Patients (ID 10113)
09:30 - 09:30 | Author(s): I. Kapfhammer
- Abstract
Background:
Targeted therapy is becoming increasingly important and has improved the overall survival for patients with NSCLC. BRAF[V600E] mutations (Val600Glu) are observed in 1-2% of lung cancer and play a major role in targeted therapy by providing an opportunity for affected patients as possible allocable target. In Austria an effective therapy is available with Dabrafenib and Trametinib. The aim of this retrospective analysis was to support ongoing research on the frequency of this promising genetic alteration by determining the prevalence of BRAF[V600E] mutations among Austrian NSCLC patients. We also examined clinical characteristics of these patients.
Method:
Patient characteristics including age, sex, race, smoking history and localization of biopsy were collected. Tumor tissue from bronchoscopy, CT- and ultrasound guided biopsies as well as surgical specimen with histological type of adenocarcinoma and NSCLC NOS (Not Otherwise Specified) excluding large cell carcinoma and neuroendocrine carcinoma was reflex tested independent of the tumor stage and clinical characteristics (like sex, smoking history, demography) for BRAF mutations. The BRAF mutation detection was performed since February 2017 with the BRAF/NRAS Mutation Test Kit from Roche on a COBAS[®] z 4800 Analyzer.
Result:
BRAF alterations were found in 11 of 118 tested patients (9.3%), of which 7 patients (5.9 %) showed a BRAF[V600E] positive mutation. Out of these patients with BRAF[V600E] positive mutation, 4 were women and 3 men. 3 patients were Never-Smoker, 2 were former smokers and 2 smokers. Biopsies in 5 patients were taken from the primary tumor, in 1 patient from the lymph nodes and in 1 patient the analysis was performed by drainage of pleura effusions. Median age was 69 years. All patients were Caucasian.
Conclusion:
The prevalence of BRAF[V600E] mutation in this real-world data, assessed in a cohort of 118 people, was higher than BRAF[V600E] mutation rates previously reported by other published data, and thus underline the importance of reflex testing for this druggable target independent of clinical characteristics.
